Benzinga's Microcap Movers for Thursday April 26, 2012

Below are highlights from Benzinga's daily coverage of microcap securities making big moves: Gold Standard Ventures Corp Shares of Gold Standard Ventures Corp (GDVXF), the Vancouver, BC exploration stage company, focusing on the acquisition and exploration of gold projects, rose 46.28% Thursday on almost 6 times the average daily volume. Gold Standard Ventures reported Thursday that a new hole, RR 12-1, has intersected 537 feet (164 meters) of 0.099 ozAu/st (3.38 g/t Au) including 140 feet (42.7 meters) of 0.274 oz Au/st (9.40 g/t Au). This intersection includes 12 intercepts (each about 5 feet in length) which assayed greater than 0.3 ozAu/st (10 g/t Au) to as high as 0.75 ozAu/st (25.6 g/t Au). Dave Mathewson, Gold Standard's Vice President of Exploration, stated that, "We are drilling a large zone of strong gold mineralization that remains open in almost all directions. This mineralization has all the characteristics expected of a large and strong gold system and is typical of some of the major gold deposits located on the Carlin Trend and elsewhere in Nevada." Gold Standard Ventures closed at $2.63 on Thursday. Vitamin Spice Vitamin Spice (VTMS), the Wayne PA developer, manufacturer, and marketer of a line of vitamin-enriched gourmet spices, rose 240% Thursday on almost 5 million shares. VitaminSpice announced Wednesday that the Federal Bankruptcy Court for the Eastern District of Pennsylvania has dismissed the involuntary bankruptcy petition that was filed against the company by its former attorney Jehu Hand, Ray Suprenard, Jeremiah Hand, John Robison, and Esthetics World. During the proceedings, petitioner John Robison admitted to providing investment funds via Kevin Lee Woodbridge, a convicted felon on securities violations. According to the SEC website, Woodbridge was banned for life from working with any public company in addition to Woodbridge's incarceration. Vitamin Spice closed at $0.03 on Thursday. Repligen Corporation Shares of Repligen RGEN, the Waltham, MA manufacturer and supplier of biologic products used to manufacture biologic drugs, fell 40.22% Thursday on 17 times the average daily volume. Repligen announced Thursday that midday Wednesday, the FDA notified the Company that the FDA Advisory Committee meeting previously scheduled for May 31 to review RG1068 for pancreatic imaging has been cancelled by the FDA. The Company expects to receive a Complete Response letter on the previously announced June 21 PDUFA date requesting additional clinical trial data to support the New Drug Application. “While we are disappointed in this result, we continue to believe that RG1068 is a safe and effective agent for imaging of the pancreatic ducts, and that it has the potential to meet a significant unmet patient need,” stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. “We intend to continue our dialogue with the FDA to assess a potential path forward for RG1068.” Repligen Corporation closed at $4.34 on Thursday. The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.